Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$23.69 USD
-0.40 (-1.64%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $23.68 -0.01 (-0.04%) 7:00 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Viking Therapeutics, Inc.'s return on equity, or ROE, is -19.98% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that VKTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
VKTX 23.69 -0.40(-1.64%)
Will VKTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Other News for VKTX
VKTX forms Stochastic Reached Oversold on September 15
VKTX's price falls by 3.61% on September 12, though its technical setup remains stable.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
SA Asks: Which biotechs could be acquired by year's end?
Is VKTX building bearish momentum? 180 Bearish Setup shows up after declining 0.5%